Eli Lilly and Company Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Eli Lilly and Company's estimated annual revenue is currently $27.8B per year.(i)
  • Eli Lilly and Company's estimated revenue per employee is $625,267
  • Eli Lilly and Company's current valuation is $233.5B. (January 2022)

Employee Data

  • Eli Lilly and Company has 44397 Employees.(i)
  • Eli Lilly and Company grew their employee count by 4% last year.

Eli Lilly and Company's People

NameTitleEmail/Phone
1
Associate VP Global Commercial Transformation and Lilly USA OperationsReveal Email/Phone
2
VPReveal Email/Phone
3
Associate VP, Strategic Business Partner-Global Manufacturing and QualityReveal Email/Phone
4
Associate VP, Clinical Development, ImmunologyReveal Email/Phone
5
Associate VP Marketing, Diabetes Business UnitReveal Email/Phone
6
Associate VP, Assistant General Counsel - Lilly Diabetes AllianceReveal Email/Phone
7
Associate VP, Real World Evidence StrategyReveal Email/Phone
8
Associate VP, Global/US Oncology MarketingReveal Email/Phone
9
Associate VP - Site Head - Indy Device ManufacturingReveal Email/Phone
10
Associate VP and Assistant General Counsel—Regulatory LegalReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.6M230%N/AN/A
#2
$23.5M117-28%N/AN/A
#3
$575.7M28642%N/AN/A
#4
$1.8M18-10%$1.5MN/A
#5
$5.8M29-6%N/AN/A
#6
$10.7M5315%N/AN/A
#7
$271.4M13504%N/AN/A
#8
$9.2M4610%N/AN/A
#9
$27760M443974%N/AN/A
#10
$1.2M6-54%N/AN/A
Add Company

What Is Eli Lilly and Company?

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaboration with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world\'s most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

keywords:N/A

N/A

Total Funding

44397

Number of Employees

$27.8B

Revenue (est)

4%

Employee Growth %

$233.5B

Valuation

N/A

Accelerator

Eli Lilly and Company News

2022-04-20 - Eli Lilly & Co. stock underperforms Wednesday when compared to competitors

Eli Lilly & Co. stock underperforms Wednesday when compared to competitors. Published: April 20, 2022 at 5:04 p.m. ET. By. MarketWatch Automation.

2022-03-30 - Lilly Presents Updated Data on Retevmo® (selpercatinib) in ...

INDIANAPOLIS , April 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 LIBRETTO-001 trial of...

2022-03-22 - Majority of Patients Treated with Lebrikizumab Achieved Skin ...

... in the ADvocate program, Eli Lilly and Company (NYSE: LLY) announced today at the American Academy of Dermatology (AAD) Annual Meeting.

2021-10-14 - Eli Lilly and : Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology

INDIANAPOLIS, Oct. 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of horm ...

2021-10-07 - Eli Lilly and : Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

INDIANAPOLIS, Oct. 7, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that preclinical characterization data for two new agents, LOXO-783 and LOXO-435, will be presented at the 2021 AACR-NCI-EORTC Virtual Interna ...